[go: up one dir, main page]

MX2012006720A - Composicion farmceutica para el tratamiento de sindrome del ojo seco. - Google Patents

Composicion farmceutica para el tratamiento de sindrome del ojo seco.

Info

Publication number
MX2012006720A
MX2012006720A MX2012006720A MX2012006720A MX2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A MX 2012006720 A MX2012006720 A MX 2012006720A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical composition
dry eye
eye syndrome
compositions
Prior art date
Application number
MX2012006720A
Other languages
English (en)
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Guenther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012006720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of MX2012006720A publication Critical patent/MX2012006720A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona nuevas composiciones farmacéuticas para el tratamiento de la queratoconjuntivitis seca que comprenden vehículos líquidos que incluyen uno o más alcanos semifluorados. Las composiciones incorporan un ingrediente activo escogido entre el grupo de inmunosupresores de macrolida. Se pueden administrar por vía tópica al ojo. La invención además proporciona estuches que comprenden dichas composiciones.
MX2012006720A 2009-12-14 2010-12-13 Composicion farmceutica para el tratamiento de sindrome del ojo seco. MX2012006720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
MX2012006720A true MX2012006720A (es) 2012-07-30

Family

ID=41731659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006720A MX2012006720A (es) 2009-12-14 2010-12-13 Composicion farmceutica para el tratamiento de sindrome del ojo seco.

Country Status (15)

Country Link
US (1) US8614178B2 (es)
EP (2) EP2335735A1 (es)
JP (5) JP5663595B2 (es)
KR (2) KR101722039B1 (es)
CN (1) CN102652022B (es)
AU (1) AU2010333039B2 (es)
BR (3) BR122020020872B1 (es)
CA (2) CA2941956C (es)
DK (1) DK2512515T3 (es)
ES (1) ES2449308T3 (es)
IN (1) IN2012DN03128A (es)
MX (1) MX2012006720A (es)
PL (1) PL2512515T3 (es)
PT (1) PT2512515E (es)
WO (1) WO2011073134A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4108216A1 (en) 2009-06-03 2022-12-28 Forsight Vision5, Inc. Anterior segment drug delivery
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN103561724B (zh) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 给药给甲的药物组合物
ES2623233T3 (es) 2011-05-25 2017-07-10 Novaliq Gmbh Composición farmacéutica tópica a base de alcanos semifluorados
JP6084987B2 (ja) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー セミフッ素化アルカンに基づく安定化タンパク質組成物
TR201812013T4 (tr) 2012-09-12 2018-09-21 Novaliq Gmbh Göz yikama bi̇leşi̇mleri̇.
EP3100722B1 (en) * 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
US9770508B2 (en) * 2012-09-12 2017-09-26 Novaliq Gmbh Semifluorinated alkane compositions
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
JP6304475B2 (ja) * 2013-01-31 2018-04-04 ロート製薬株式会社 点眼剤
JP6265793B2 (ja) * 2013-03-13 2018-01-24 参天製薬株式会社 マイボーム機能不全の治療剤
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
US20160243291A1 (en) * 2013-10-15 2016-08-25 Forsight Vision5, Inc. Formulations and Methods for Increasing or Reducing Mucus
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11013403B2 (en) * 2015-09-29 2021-05-25 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
ES2953837T3 (es) * 2015-09-30 2023-11-16 Novaliq Gmbh 2-perfluorobutil pentano para administración oftálmica
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
US11684589B2 (en) 2016-09-22 2023-06-27 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
EP3515467B1 (en) * 2016-09-23 2023-11-29 Novaliq GmbH Ophthalmic compositions comprising ciclosporin
MX2019003544A (es) * 2016-09-28 2019-09-19 Novaliq Gmbh Composiciones que comprenden un ligando de union al receptor cannabinoide.
AU2017380769B2 (en) * 2016-12-22 2023-12-21 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
PT3399962T (pt) * 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
EP3565520A4 (en) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2018193093A1 (en) * 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
CN110650734B (zh) * 2017-05-12 2024-11-15 诺瓦利克有限责任公司 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN119909046A (zh) 2017-10-04 2025-05-02 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019206956A1 (en) 2018-04-27 2019-10-31 Novaliq Gmbh Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
KR20210080388A (ko) 2018-09-22 2021-06-30 노바리크 게엠베하 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
KR102808092B1 (ko) 2018-09-27 2025-05-22 더마리크 테라퓨틱스, 인크. 지질 장벽 수복
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113518619A (zh) * 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
WO2020165132A1 (en) 2019-02-13 2020-08-20 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
CA3141386A1 (en) 2019-05-24 2020-12-03 Novaliq Gmbh Ophthalmic composition for the treatment of ocular allergy
WO2021044045A1 (en) 2019-09-06 2021-03-11 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
IL322635A (en) * 2023-02-13 2025-10-01 Novaliq Gmbh Ophthalmic preparation for eye surgery in patients with ocular surface disease
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) * 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE19861012A1 (de) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CZ20013769A3 (cs) * 1999-04-30 2002-03-13 Sucampo Ag Činidlo pro léčbu suchého oka
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
EP1740189B1 (en) * 2004-04-19 2012-06-13 Centre National De La Recherche Scientifique -Cnrs- Lung surfactant supplements
US20050288197A1 (en) * 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Silicone polymer topical eye compositions and methods of use
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
DK2110126T3 (da) 2008-04-18 2012-02-27 Novaliq Gmbh Inhalations- og instillationsanvendelse af semifluorerede alkaner som aktiv bestanddel-bærere inden for det intrapulmonale område

Also Published As

Publication number Publication date
JP6096731B2 (ja) 2017-03-15
JP6731039B2 (ja) 2020-07-29
KR20160105533A (ko) 2016-09-06
JP2019070003A (ja) 2019-05-09
IN2012DN03128A (es) 2015-09-18
KR101722039B1 (ko) 2017-03-31
KR20120115977A (ko) 2012-10-19
JP6397472B2 (ja) 2018-09-26
EP2512515B1 (en) 2013-12-25
BR112012014190A2 (pt) 2016-05-31
JP2013513586A (ja) 2013-04-22
BR122020020872B1 (pt) 2021-09-08
US8614178B2 (en) 2013-12-24
BR112012014190B1 (pt) 2021-03-02
CA2941956A1 (en) 2011-06-23
CA2941956C (en) 2018-09-04
WO2011073134A1 (en) 2011-06-23
EP2335735A1 (en) 2011-06-22
CN102652022A (zh) 2012-08-29
AU2010333039B2 (en) 2014-08-28
CN102652022B (zh) 2014-12-17
PT2512515E (pt) 2014-03-04
JP2015028064A (ja) 2015-02-12
JP2017078086A (ja) 2017-04-27
CA2776860C (en) 2016-10-25
PL2512515T3 (pl) 2014-05-30
HK1172269A1 (en) 2013-04-19
JP2019006803A (ja) 2019-01-17
DK2512515T3 (en) 2014-03-10
EP2512515A1 (en) 2012-10-24
CA2776860A1 (en) 2011-06-23
BR112012014190B8 (pt) 2021-05-25
BR122017018955B1 (pt) 2022-03-08
AU2010333039A1 (en) 2012-07-12
US20120244177A1 (en) 2012-09-27
KR101652714B1 (ko) 2016-09-01
ES2449308T3 (es) 2014-03-19
JP5663595B2 (ja) 2015-02-04

Similar Documents

Publication Publication Date Title
MX2012006720A (es) Composicion farmceutica para el tratamiento de sindrome del ojo seco.
MX389597B (es) Inhibidores de cdk2/4/6 de piridopirimidinona.
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
NZ708593A (en) Novel pyrazole derivative
WO2014047427A3 (en) Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
CL2008003798A1 (es) Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MX2015003229A (es) Composiciones que comprenden mezclas de alcanos semifluorados.
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
WO2014028931A3 (en) Compounds and methods for treating mammalian gastrointestinal microbial infections
BR112012007332A2 (pt) nova composição farmacêutica que compreende um macrólido imunossupressor
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
EP4414376A3 (en) Novel depsipeptide and uses thereof
EP3216798A3 (en) Ketolide compounds
MX341220B (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
CL2012003521A1 (es) Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.
BR112017009510A2 (pt) composições compreendendo ciclosporina
WO2015150449A3 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
BRPI0913297B8 (pt) composição farmacêutica estabilizada
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
MX2018002821A (es) Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv

Legal Events

Date Code Title Description
FG Grant or registration